Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …
被引用次数：79 相关文章

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2022 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> The immunogenicity and
reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood.</jats …

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2022 - research.monash.edu
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2021 - europepmc.org
Purpose The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. Methods We performed a prospective cohort study of adults …

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study.

V Naranbhai, CA Pernat, A Gavralidis, KJ St Denis… - 2022 - cabidigitallibrary.org
Purpose: The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. Methods: We performed a prospective cohort study of adults …

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

V Naranbhai, CA Pernat… - Journal of …, 2022 - mdanderson.elsevierpure.com
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

V Naranbhai, CA Pernat… - Journal of clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. Methods We performed a prospective cohort study of adults …
[HTML] nih.gov

[HTML][HTML] Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.

V Naranbhai, CA Pernat, A Gavralidis… - Journal of Clinical …, 2021 - europepmc.org
Purpose The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. Methods We performed a prospective cohort study of adults …